Compare HRB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | LNTH |
|---|---|---|
| Founded | 1955 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 6.5B |
| IPO Year | 1994 | 2014 |
| Metric | HRB | LNTH |
|---|---|---|
| Price | $36.31 | $103.83 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $41.00 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 2.2M | 898.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 3.38 | 1.80 |
| Revenue | ★ $3,159,931,000.00 | $343,374,000.00 |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.21 | $14.19 |
| P/E Ratio | ★ $10.62 | $57.96 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $28.16 | $47.27 |
| 52 Week High | $56.76 | $104.50 |
| Indicator | HRB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 68.01 |
| Support Level | $29.24 | $93.33 |
| Resistance Level | $39.96 | N/A |
| Average True Range (ATR) | 1.19 | 3.52 |
| MACD | -0.50 | -0.00 |
| Stochastic Oscillator | 19.10 | 92.79 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.